Andrew Alliance S.A., the robotics company that is improving repeatability with an innovative approach to liquid handling with conventional laboratory pipettes, today announced a $14 million investment by several of the leading life sciences enterprises, including Tecan Group, the Waters Corporation, Inpeco, Rancilio Cube, Sam Eletr Trust and Omega Funds.
The C-round investment brings together a strategic mix of globally recognized life sciences market leaders, along with private equity investors and including existing investors.
“We are delighted to expand our team of investors and partners with the industry’s most recognized companies,” said Piero Zucchelli, CEO and a co-founder of Andrew Alliance. “It’s particularly meaningful that both Tecan and Waters appreciate how we’re making robotics accessible to more scientists.”
The Tecan Group is the world leader for automated liquid handling solutions, and Waters has pioneered chromatography, mass spectrometry and thermal analysis innovations serving the life, materials and food sciences for nearly 60 years. Both companies are considered technology leaders in their respective fields.
“Andrew Alliance’s robot changes the game for repeatability – and further improves our customers’ operational efficiency,” said Paul Tardif, senior director of corporate development at Waters. “The Andrew robots are extraordinarily affordable and solve a persistent problem. Our customers are eager for a ready-to-use solution like this.”
In just four years, Andrew Alliance has become the leading choice for life science bench robotics. It’s relied on by 18 of the top 20 pharmaceutical companies, the top four diagnostic companies and 16 of the top 20 of the world’s leading academic research institutions.
Andrew Alliance’s flagship offering is a family of flexible, software-driven robot models, each with a footprint about the size of a standard piece of paper. The robots work right out of the box and deliver absolute consistency in how liquids are measured and tested, using standard pipettes and consumables. Andrew performs its job within a few minutes of setup.
“Andrew Alliance’s affordable benchtop robots using conventional pipettes are a new and complementary approach to Tecan’s workstations, which help customers to automate a wide variety of laboratory workflows in research and clinical diagnostics,” said David Martyr, CEO of Tecan.
Andrew Alliance will use the funds for continuous product innovation and strategic industry partnerships. It also will extend its close collaboration with customers worldwide to refine future offerings.
“Demand for better reproducibility continues to increase,” said Otello Stampacchia, managing director and founder of Omega Funds, an early investor.
“The ongoing innovation in life science creates a vast opportunity for new automated tools and approaches like Andrew’s robots,” said Sam Eletr, a member of the founding team and an early investor.
About Andrew Alliance
Andrew Alliance is advancing science with a new class of high-performance, easy-to-use robots that dramatically improve the repeatability, performance and speed of liquid handling. This new approach, and Andrew, the flagship robot, are winning awards and rapidly transforming bench research in hundreds of pharmaceutical, diagnostic and academic laboratories worldwide, by eliminating routine pipetting errors and time-consuming manual efforts. Visit andrewalliance.com to see how it works.